MILESTONE PHARMACEUTICALS INC. Milestone Pharmaceuticals Inc. Share Price
Equities
MIST
CA59935V1076
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.54 USD | -2.53% |
|
-6.10% | -7.78% |
| Sales 2024 * | - | Sales 2025 * | 13.5M 1.13B | Capitalization | 96.6M 8.05B |
|---|---|---|---|---|---|
| Net income 2024 * | -59M -4.92B | Net income 2025 * | -82M -6.84B | EV / Sales 2024 * | - |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 7.16 x |
| P/E ratio 2024 * |
-1.34
x | P/E ratio 2025 * |
-1
x | Employees | 47 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.37% |
More Fundamentals
* Assessed data
More news
Latest transcript on Milestone Pharmaceuticals Inc.
More recommendations
More press releases
| 1 day | -2.53% | ||
| 1 week | -6.10% | ||
| Current month | -13.97% | ||
| 1 month | -14.44% | ||
| 6 months | -32.46% | ||
| Current year | -7.78% |
1 week
1.50
1.72
1 month
1.501.87
Current year
1.332.40
1 year
1.334.49
3 years
1.339.85
5 years
0.0027.95
10 years
0.0027.95
| Managers | Title | Age | Since |
|---|---|---|---|
Joseph Oliveto
CEO | Chief Executive Officer | 56 | 07/17/07 |
Amit Hasija
DFI | Director of Finance/CFO | 51 | 09/19/09 |
Anita Holz
CTO | Chief Tech/Sci/R&D Officer | - | 01/22/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Seth Fischer
BRD | Director/Board Member | 68 | 21/23/21 |
Joseph Oliveto
CEO | Chief Executive Officer | 56 | 07/17/07 |
Debra Liebert
BRD | Director/Board Member | 67 | 01/15/01 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1.54 | -2.53% | 469,849 |
| 25/24/25 | 1.58 | -4.82% | 253,033 |
| 24/24/24 | 1.66 | -2.35% | 48,684 |
| 23/24/23 | 1.7 | +4.29% | 90,452 |
| 22/24/22 | 1.63 | -0.61% | 34,803 |
Delayed Quote Nasdaq, April 27, 2024 at 02:00 am IST
More quotes
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Calendar
15/05/2024
- Q1 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.54
USD
Average target price
10.5
USD
Spread / Average Target
+581.82%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -7.78% | 96.6M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- MIST Stock
